Catherine C. Coombs, MD, is a hematologist-oncologist at the University of California, Irvine.
Unmet Needs and Clinical Pearls for Treating Relapsed/Refractory CLL
Catherine C. Coombs, MD, discusses unmet needs and offers advice for community oncologists treating patients with relapsed/refractory chronic lymphocytic leukemia.
Recent Data on CAR T-Cell Therapy and BTK Inhibitors in Relapsed/Refractory CLL
An overview of recent data from ongoing trials evaluating CAR T-cell therapy and BTK inhibitors in patients with relapsed/refractory CLL.
MURANO: Venetoclax Plus Rituximab in Patients With Relapsed/Refractory CLL
An expert oncologist reviews the MURANO trial of venetoclax plus rituximab in patients with relapsed/refractory CLL and discusses MRD as a parameter of treatment response.
Overview of Treatment Options for Relapsed/Refractory CLL
Catherine C. Coombs, MD, reviews currently available treatment options for patients with relapsed/refractory chronic lymphocytic leukemia.
CLL: Prognostic Factors and Treatment Considerations
An expert on chronic lymphocytic leukemia discusses disease progression and prognostic factors that influence treatment decisions.
Patient Profile: A 70-Year-Old Man with Relapsed/Refractory CLL
Catherine C. Coombs, MD, presents the case of a 70-year-old man with relapsed/refractory chronic lymphocytic leukemia and offers her initial impressions.
Novel Treatments and Combinations for the Treatment of Patients With CLL
Catherine Coombs, MD, MS, shares her thoughts on the future of treatment and where the field is moving for patients with CLL.
Emerging Treatment Options for Patients with R/R CLL
A detailed description of emerging treatment options for patients with relapsed/refractory CLL.
Considerations For Retreatment With Venetoclax in R/R CLL
Catherine Coombs, MD, MS, highlights available data and considerations for retreatment with venetoclax in the relapsed/refractory setting.
Existing Options for Second-Line Treatment of Patients with R/R CLL
A comprehensive review of existing second-line treatment options for patients with R/R CLL.
Patient Factors for Selecting Treatment in R/R CLL
Catherine Coombs, MD, MS, reviews factors that impact the selection of treatment in patients with CLL.
Considerations and Triggers for Initiation of Treatment in a Patient with R/R CLL
An expert in treating CLL discusses potential treatment options for a patient with relapsed/refractory CLL who has been previously treated with venetoclax plus obinutuzumab.
Initial Impression and Prognosis of a Patient with R/R CLL
Catherine Coombs, MD, MS, introduces the case of a patient with relapsed/refractory CLL and shares her impressions on the patient’s initial presentation.
Follow-up Studies Explore Pirtobrutinib in Chronic Lymphocytic Leukemia
Catherine Callaghan Coombs, MD, discusses 2 upcoming trials in chronic lymphocytic leukemia.
